Phosphorylcholine-based polymer coatings for stent drug delivery

  • A. L. Lewis
  • T. A. Vick
  • A. C. M. Collias
  • L. G. Hughes
  • R. R. Palmer
  • S. W. Leppard
  • J. D. Furze
  • A. S. Taylor
  • P. W. Stratford
Article

Abstract

Phosphorylcholine-based polymers have been used commercially to improve the biocompatibility of coronary stents. In this study, one particular polymer is assessed for its suitability as a drug delivery vehicle. Membranes of the material are characterized in terms of water content and molecular weight cut-off, and the presence of hydrophilic and hydrophobic domains investigated by use of the hydrophobic probe pyrene. The in vitro loading and elution of a variety of drugs was assessed using stents coated with the polymer. The rate of a drug's release was shown not to be simply a function of its water solubility, but rather more closely related to the drug oil/water partition coefficient. This finding was explained in terms of the more hydrophobic drugs partitioning into, and interacting with, the hydrophobic domains of the polymer coating. The suitability of the coated stent as a drug delivery vehicle was assessed in vivo using a radiolabeled analog of one of the more rapidly eluting drugs, angiopeptin. Autoradiography showed that the drug was released locally to the wall of the stented artery, and could be detected up to 28 days after implantation.

© 2001 Kluwer Academic Publishers

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    A. L. Lewis, P. W. Stratford, A. L. Lewis, R. T. Freeman, L. Hughes, R. P. Redman, L. A. Tolhurst and T. A. Vick, Abstracts of UKSB 1st Annual Conference, July 2000.Google Scholar
  2. 2.
    A. L. Lewis, Colloids Surf. B: Biointerfaces 18 (2000) 261.Google Scholar
  3. 3.
    W. J. Van der Giessen, A. M. Lincoff, R. S. Schwartz, H. M. M. Van Beusekom, P. W. Serruys, D. R. Holmes, S. G. Ellis and E. J. Topol, Circulation 94(7) (1996) 1690.Google Scholar
  4. 4.
    A. L. Lewis, L. A. Tolhurst and P. W. Stratford, Biomaterials in press (2001).Google Scholar
  5. 5.
    A. M. McNair, Med. Dev. Tech. 7(10) (1996) 16.Google Scholar
  6. 6.
    A. L. Lewis, Z. L. Cumming, H. H. Goreish, L. C. Kirkwood, L. A. Tolhurst and P. W. Stratford Biomaterials 22 (2001) 99.Google Scholar
  7. 7.
    E. F. Murphy, J. R. Lu, A. L. Lewis, J. Brewer, J. Russell and P. W. Stratford, Macromolecules 33(12) (2000) 4545.Google Scholar
  8. 8.
    S. L. Willis, J. L. Court, R. P. Redman, J. H. Wang, S. W. Leppard, V. O'byrane, S. A. Small, A. L. Lewis, S. A. Jones and P. W. Stratford Biomaterials in the press.Google Scholar
  9. 9.
    K. Kalyanasundaram and J. K. Thomas, J. Am. Chem. Soc. 99(7) (1977) 2039.Google Scholar
  10. 10.
    K. Ishihara, Y. Iwasaki and N. Nakabayashi, Polym. J. 31(12) (1999) 1231.Google Scholar
  11. 11.
    J. Gunn, Oral presentation, 6th Int. LDD&R Mtg, January 2000.Google Scholar
  12. 12.
    P. H. Corkhill, A. M. Jolly, C. O. Ng and B. J. Tighe, Polymer 28 (1987) 1758.Google Scholar
  13. 13.
    Y. Tang, J. R. Lu, A. L. Lewis, T. A. Vick and P. W. Stratford Macromolecules (2001) submitted.Google Scholar
  14. 14.
    CE mark for the BiodivYsio Matrix HI drug delivery stent system, 2001.Google Scholar
  15. 15.
    M. L. Foegh, S. Asotra, J. V. Conte, M. Howell, E. Kagan, K. Verma and P. W. Ramwell, J. Vasc. Surg. 19 (1994) 1084.Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • A. L. Lewis
    • 1
  • T. A. Vick
    • 1
  • A. C. M. Collias
    • 1
  • L. G. Hughes
    • 1
  • R. R. Palmer
    • 1
  • S. W. Leppard
    • 1
  • J. D. Furze
    • 1
  • A. S. Taylor
    • 1
  • P. W. Stratford
    • 1
  1. 1.Biocompatibles Ltd.Farnham, SurreyUK

Personalised recommendations